Alzheimer's disease, Lancet, vol.388, pp.505-522, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01579097
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage, Brain, vol.138, pp.1327-1365, 2015. ,
Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: the ABIDE project, Alzheimers Dement (N Y), vol.3, pp.314-336, 2017. ,
Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer's biomarkers in daily practice (ABIDE) project, JAMA Neurol, vol.74, pp.1481-91, 2017. ,
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers, Alzheimers Dement, vol.13, pp.903-915, 2017. ,
Cerebrospinal fluid A?42 is the best predictor of clinical progression in patients with subjective complaints, Alzheimers Dement, vol.9, pp.481-87, 2013. ,
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification, Neurobiol Aging, vol.32, pp.2322-2341, 2011. ,
Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology, Neurology, vol.90, pp.126-161, 2018. ,
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers, Lancet Neurol, vol.16, pp.661-76, 2017. ,
NIAAA Research Framework: toward a biological definition of Alzheimer's disease, Alzheimers Dement, vol.14, pp.535-62, 2018. ,
External validation of a Cox prognostic model: principles and methods, BMC Med Res Methodol, vol.13, p.33, 2013. ,
Optimizing patient care and research: the Amsterdam Dementia Cohort, J Alzheimers Dis, vol.41, pp.313-340, 2014. ,
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimers Dement, vol.1, pp.55-66, 2005. ,
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease, Neurology, vol.85, pp.1240-1289, 2015. ,
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA study, Neuroepidemiology, vol.30, pp.254-65, 2008. ,
, For the Foundation for the National Institutes of Health see https://fnih.org For the complete list of ADNI investigators see, For the ADNI database see
AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease, Ann N Y Acad Sci, vol.1180, pp.36-46, 2009. ,
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network, Dement Geriatr Cogn Disord, vol.27, pp.404-421, 2009. ,
Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation, Neurobiol Aging, vol.59, pp.72-79, 2017. ,
Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiol Aging, vol.33, pp.2533-50, 2012. ,
Markers of Alzheimer's disease in a population attending a memory clinic, Alzheimers Dement, vol.5, pp.307-324, 2009. ,
Underlying biological processes in mild cognitive impairment: amyloidosis versus neurodegeneration, J Alzheimers Dis, vol.64, issue.1, pp.647-57, 2018. ,
Longitudinal changes of CSF biomarkers in Alzheimer's disease, J Alzheimers Dis, vol.25, pp.583-94, 2011. ,
Data mining methods in the prediction of dementia: a realdata comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests, BMC Res Notes, vol.4, p.299, 2011. ,
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement, BMJ, vol.350, p.7594, 2015. ,
Impact of the Alzheimer's Disease Neuroimaging Initiative, Alzheimers Dement, vol.11, pp.865-84, 2004. ,
Development and usability of ADappt-an online tool to support clinicians, patients and caregivers in the diagnosis of mild cognitive impairment and Alzheimer's disease, JMIR Form Res, vol.3, p.13417, 2019. ,
Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review, Alzheimers Res Ther, vol.10, p.72, 2018. ,
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.270-79, 2011. ,
Added value of amyloid PET in individualized risk predictions for MCI patients, Alzheimers Dement (Amst), vol.11, pp.529-566, 2019. ,
Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations, Med Decis Making, vol.27, pp.696-713, 2007. ,
Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicentre memory clinic cohort: the ABIDE project, Alzheimers Dement (Amst), vol.10, pp.563-72, 2018. ,